WallStSmart

Alcon AG (ALC)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 150199% more annual revenue ($10.40B vs $6.92M). NNNN leads profitability with a 37.2% profit margin vs 9.4%. ALC trades at a lower P/E of 37.5x. ALC earns a higher WallStSmart Score of 49/100 (D+).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 7.3
Piotroski: 4/9

NNNN

Hold

37

out of 100

Grade: F

Growth: 5.3Profit: 8.0Value: 3.0Quality: 7.8
Piotroski: 4/9Altman Z: 9.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-489.8%)

Margin of Safety

-489.8%

Fair Value

$13.46

Current Price

$75.26

$61.80 premium

UndervaluedFair: $13.46Overvalued
NNNNSignificantly Overvalued (-3894.1%)

Margin of Safety

-3894.1%

Fair Value

$0.68

Current Price

$23.76

$23.08 premium

UndervaluedFair: $0.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

NNNN3 strengths · Avg: 10.0/10
Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
73.5%10/10

Strong operational efficiency at 73.5%

Altman Z-ScoreHealth
9.0810/10

Safe zone — low bankruptcy risk

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

EPS GrowthGrowth
-22.2%2/10

Earnings declined 22.2%

NNNN4 concerns · Avg: 2.8/10
EPS GrowthGrowth
2.8%4/10

2.8% earnings growth

Market CapQuality
$1.02B3/10

Smaller company, higher risk/reward

P/E RatioValuation
386.5x2/10

Premium valuation, high expectations priced in

Price/BookValuation
37.7x2/10

Trading at 37.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : NNNN

The strongest argument for NNNN centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 37.2% and operating margin at 73.5%.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : NNNN

The primary concerns for NNNN are EPS Growth, Market Cap, P/E Ratio. A P/E of 386.5x leaves little room for execution misses.

Key Dynamics to Monitor

ALC profiles as a value stock while NNNN is a declining play — different risk/reward profiles.

ALC is growing revenue faster at 8.6% — sustainability is the question.

ALC generates stronger free cash flow (489M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALC scores higher overall (49/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Anbio Biotechnology Class A Ordinary Shares

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.

Want to dig deeper into these stocks?